SRPT250110P120000
- 4.82
- 0.000.00%
Sarepta Therapeutics Newsroom
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Sarepta Therapeutics: A Promising Investment With Strategic Market Position and Innovative ARO-DM1 Program
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $165
RBC Cuts Price Target on Sarepta Therapeutics to $165 From $182, Keeps Outperform Rating
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $217
Sarepta Therapeutics (SRPT) Gets a Buy From Bank of America Securities
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Sarepta Therapeutics (NASDAQ:SRPT) Delivers Shareholders Respectable 18% CAGR Over 3 Years, Surging 4.2% in the Last Week Alone
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Jefferies Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $165
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Kymera Therapeutics (KYMR) and Sarepta Therapeutics (SRPT)
Sarepta Therapeutics: Buy Rating Backed by Elevidys Growth and Diversified Pipeline
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now?
Sarepta Awarded $115.2M in Vyondys 53 Patent Case: Report
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Mizuho Securities Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)